Dr. West on NSCLC Afatinib and Cetuximab Combination

Dr. H. Jack West from Swedish Cancer Institute discusses Afatinib and Cetuximab Combination in NSCLC

H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington discusses some of the results from the phase II trial combining two therapies, afatinib and cetuximab, in patients with T790M mutated as a mechanism of resistance in non-small cell lung cancer (NSCLC). He describes that the benefit not only helped T790M patients but also those without the mutation.